592 related articles for article (PubMed ID: 25447989)
21. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
Mercier K; Smith H; Biederman J
Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
[TBL] [Abstract][Full Text] [Related]
22. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
Slagman MC; Navis G; Laverman GD
Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
[TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system.
Nussberger J; Bohlender J
Nat Rev Cardiol; 2013 Apr; 10(4):183-4. PubMed ID: 23478259
[TBL] [Abstract][Full Text] [Related]
24. Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
Chen SS; Seliger SL; Fried LF
Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):449-55. PubMed ID: 25014549
[TBL] [Abstract][Full Text] [Related]
25. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
Abassi Z; Winaver J; Feuerstein GZ
Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.
Susantitaphong P; Sewaralthahab K; Balk EM; Eiam-ong S; Madias NE; Jaber BL
Am J Hypertens; 2013 Mar; 26(3):424-41. PubMed ID: 23382494
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
[TBL] [Abstract][Full Text] [Related]
28. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Bomback AS; Toto R
Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacological differences between inhibitor drugs of the renin-angiotensin aldosterone system].
Méndez-Durán A
Rev Med Inst Mex Seguro Soc; 2011; 49(1):45-52. PubMed ID: 21513660
[TBL] [Abstract][Full Text] [Related]
30. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
31. Clinical role of direct renin inhibition in hypertension.
Taylor AA; Pool JL
Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
[TBL] [Abstract][Full Text] [Related]
32. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.
Atlas SA
J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):9-20. PubMed ID: 17970613
[TBL] [Abstract][Full Text] [Related]
33. Medical Therapies for Heart Failure With Preserved Ejection Fraction.
Kjeldsen SE; von Lueder TG; Smiseth OA; Wachtell K; Mistry N; Westheim AS; Hopper I; Julius S; Pitt B; Reid CM; Devereux RB; Zannad F
Hypertension; 2020 Jan; 75(1):23-32. PubMed ID: 31786973
[TBL] [Abstract][Full Text] [Related]
34. [Renin-angiotensin-aldosteron system: evolution of views from renin discovery to nowadays. Perspectives of therapeutic block].
Shestakova MV
Ter Arkh; 2011; 83(4):71-7. PubMed ID: 21675280
[TBL] [Abstract][Full Text] [Related]
35. Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.
Beitelshees AL; Zineh I
Heart Fail Rev; 2010 May; 15(3):209-17. PubMed ID: 18351457
[TBL] [Abstract][Full Text] [Related]
36. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
37. The renin-angiotensin-aldosterone system and heart failure.
Sayer G; Bhat G
Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
[TBL] [Abstract][Full Text] [Related]
38. Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease.
Antlanger M; Bernhofer S; Kovarik JJ; Kopecky C; Kaltenecker CC; Domenig O; Poglitsch M; Säemann MD
Ann Med; 2017 Sep; 49(6):525-533. PubMed ID: 28358246
[TBL] [Abstract][Full Text] [Related]
39. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.
Gullapalli N; Bloch MJ; Basile J
Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):359-73. PubMed ID: 20965951
[TBL] [Abstract][Full Text] [Related]
40. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
Krum H; Gilbert RE
J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
